pirfenidone has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aboulkheyr Es, H; Thiery, JP; Warkiani, ME; Zhand, S | 1 |
| Stylianopoulos, T; Voutouri, C | 1 |
2 other study(ies) available for pirfenidone and Breast Neoplasms
| Article | Year |
|---|---|
Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
Topics: Antineoplastic Agents; B7-H1 Antigen; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cells, Cultured; Chemokine CCL17; Gene Expression Regulation, Neoplastic; Humans; Immunosuppression Therapy; Lymphotoxin-alpha; Neoplasm Invasiveness; Pyridones; Tumor Microenvironment | 2020 |
Accumulation of mechanical forces in tumors is related to hyaluronan content and tissue stiffness.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Elastic Modulus; Female; Humans; Hyaluronic Acid; Mammary Glands, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; ortho-Aminobenzoates; Pyridones | 2018 |